Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Tech Mahindra Limited - Allotment of ESOP/ESPS

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TCHQY 532755 TECHM

9
Accenture’s growth forecast puts spotlight on Indian rivals

2018-07-10 livemint
Bengaluru: Accenture Plc will add more than $4.37 billion in incremental revenue in the fiscal year ending August 2018, the highest new revenue done by an information technology (IT) outsourcing company in over two decades.
HCTHY INFY TCHQY TTNQY 532755 CTSH TECHM WIT 532540 HCLTECH ACN 532281 TCS

0
Tech Mahindra Limited - Updates

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TCHQY 532755 TECHM

3
Tech Mahindra CEO C.P. Gurnani’s salary was ₹ 146.19 crore in FY18

2018-07-09 livemint
Bengaluru: Tech Mahindra’s chief executive officer C.P. Gurnani earned ₹ 146.19 crore in remuneration in 2017-18, bringing his total earnings over the last five years to ₹510 crore. The numbers have rekindled debate among analysts and observers on compensation for the CEO of India’s fifth largest software services company and how it compares with the median salary of its other employees.
WIT 532540 HCLTECH HCTHY INFY 532281 TCHQY TCS TTNQY 532755 TECHM

1
TCS hits fresh record high; brokerages betting on strong Q1 earnings growth

2018-07-06 moneycontrol
Tata Consultancy Services created history on Friday as it touched a fresh record high above Rs 1,900 per share, supported by expectations of strong growth in the June quarter and depreciation in the rupee against the dollar.
500325 RELIANCE HCTHY TCHQY TTNQY 532755 TECHM 532540 HDB 500180 RIGD HCLTECH 532281 HDFCBANK TCS RLNIY

0
EXCL | Bad news for offline retailers: Govt may allow FDI in e-tailers holding inventory

2018-07-05 moneycontrol
India's offline retail industry has faced an onslaught from online commerce the past few years, funded by foreign capital. Yet, months after the $16-billion Flipkart-Walmart deal, the government is now mulling allowing FDI-funded e-commerce firms to switch over from the marketplace to inventory model, a move that could further rile traditional retailers in an election year.
TCHQY 532755 TECHM

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

Silicon Investor Message Boards

This table lists all message boards related to NSE:TECHM / TECH MAHINDRA LTD. on message board site Silicon Investor.

Techmire (TCM) turnaround/lead PE of 4!